Compare DexCom, Inc. (DXCM) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs SYSCO Corporation — how do they compare? DexCom, Inc. trades at $77.3 (market cap $28.06B), while SYSCO Corporation trades at $82.52 (market cap $38.60B). The key difference: SYSCO Corporation is the larger of the two by market cap, and SYSCO Corporation pays a 2.73% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | SYY | |
|---|---|---|
Market Cap | $28.06B | $38.60B |
Sector | Health | Consumer Staples |
52-Week High | $89.53 | $91.16 |
52-Week Low | $54.84 | $69.30 |
Enterprise Value | $27.03B | $52.08B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
SYY trades at $82.32, down 0.64% today, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results, beating in Q3 and Q4 2025 but missing in Q1 2026. Revenue growth remains steady, reaching $81.37B in 2025, while net income margin is 2.08%. The company maintains positive cash flow and announced a $0.55 dividend for July 2026.
Outlook is positive with a consensus price target of $83.67, though risks include margin pressure and debt levels. The stock offers value with a P/S of 0.47, but investors should monitor Q2 2026 earnings and industry headwinds. Institutional sentiment is bullish, with 60% buy ratings among analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
